Area of research
Surgery · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Antiplatelet Therapy and Cardiovascular Diseases, and Heart Failure Treatment and Management.
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial
Prognostic Value of Cardiovascular Biomarkers in the Population
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis
Lipoprotein(a), platelet function and cardiovascular disease
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial
Impact of Blood Lipids on 10-Year Cardiovascular Risk in Individuals Without Dyslipidemia and With Low Risk Factor Burden
Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline
Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study
Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Effect of Aspirin on Disability-free Survival in the Healthy Elderly
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease
Persistent psychological distress and mortality in patients with stable coronary artery disease
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study
Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease
Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study
Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina